Oncternal Therapeutics Inc (ONCT) Stock Price & Overview
NASDAQ:ONCT • US68236P2065
Current stock price
The current stock price of ONCT is 0.5266 USD. Today ONCT is down by -24.11%. In the past month the price decreased by -64.89%. In the past year, price decreased by -93.89%.
ONCT Key Statistics
- Market Cap
- 1.559M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.69
- Dividend Yield
- N/A
ONCT Stock Performance
ONCT Stock Chart
ONCT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ONCT. When comparing the yearly performance of all stocks, ONCT is a bad performer in the overall market: 99.68% of all stocks are doing better.
ONCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCT. ONCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ONCT Earnings
On November 6, 2024 ONCT reported an EPS of -2.86 and a revenue of 494.00K. The company beat EPS expectations (12.24% surprise) and beat revenue expectations (252.23% surprise).
ONCT Forecast & Estimates
6 analysts have analysed ONCT and the average price target is 2.04 USD. This implies a price increase of 287.39% is expected in the next year compared to the current price of 0.5266.
For the next year, analysts expect an EPS growth of 10.27% and a revenue growth 161.75% for ONCT
ONCT Groups
Sector & Classification
ONCT Financial Highlights
Over the last trailing twelve months ONCT reported a non-GAAP Earnings per Share(EPS) of -11.69. The EPS increased by 18.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| Debt/Equity | 0 |
ONCT Ownership
ONCT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 362.828B | ||
| AMGN | AMGEN INC | 15.51 | 187.828B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 171.453B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 113.963B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 78.412B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.05 | 40.854B | ||
| INSM | INSMED INC | N/A | 29.992B | ||
| NTRA | NATERA INC | N/A | 27.569B | ||
| BIIB | BIOGEN INC | 11.77 | 26.995B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.13 | 23.31B | ||
| MRNA | MODERNA INC | N/A | 20.276B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.929B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONCT
Company Profile
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Company Info
IPO: 2004-02-03
Oncternal Therapeutics Inc
12230 El Camino Real, Suite 230
San Diego CALIFORNIA 92130 US
CEO: James B. Breitmeyer
Employees: 27
Phone: 18584341113
Oncternal Therapeutics Inc / ONCT FAQ
What does Oncternal Therapeutics Inc do?
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Can you provide the latest stock price for Oncternal Therapeutics Inc?
The current stock price of ONCT is 0.5266 USD. The price decreased by -24.11% in the last trading session.
Does Oncternal Therapeutics Inc pay dividends?
ONCT does not pay a dividend.
What is the ChartMill rating of Oncternal Therapeutics Inc stock?
ONCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does Oncternal Therapeutics Inc belong to?
Oncternal Therapeutics Inc (ONCT) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for ONCT stock?
The Revenue of Oncternal Therapeutics Inc (ONCT) is expected to grow by 161.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is Oncternal Therapeutics Inc worth?
Oncternal Therapeutics Inc (ONCT) has a market capitalization of 1.56M USD. This makes ONCT a Nano Cap stock.